Clinical Podcasts Archive

Important:

Information contained in the following UpToDate Talk podcasts was current at the time of initial release. However, this content is not maintained or updated. For current clinical recommendations, please always consult UpToDate Online. Please note that we are no longer producing new clinical podcasts.

UpToDate faculty discuss important changes to the practice of medicine based in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

This is the complete archive for the UpToDate Clinical Talk Podcasts.

Peanut oral immunotherapy in children and young adults

Date Released: 5月 30 2018

This episode features Dr. Robert Wood discussing the results of a trial of oral immunotherapy with a manufactured peanut protein product for peanut desensitization, and its potential role in clinical practice. Dr. Nancy Sokol hosts.

Dr. WoodDr. Wood is Professor of Pediatrics and Director of Pediatric Allergy and Immunology at the Johns Hopkins University School of Medicine and Professor of International Health at the Johns Hopkins Bloomberg School of Public Health. He is Editor-in-Chief of the Allergy and Immunology specialty at UpToDate.
  1. Bird JA, Spergel JM, Jones SM, et al. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. J Allergy Clin Immunol Pract 2018; 6:476.

Robert A Wood, MD Grant/Research/Clinical Trial Support: DBV Technologies; Aimmune; Astellas; HAL-Allergy [Food allergy].

Digoxin levels and mortality in patients with atrial fibrillation

Date Released: 5月 23 2018

Dr. Leonard Ganz discusses pharmacologic rate control of atrial fibrillation (AF) and findings of a recent study published in the Journal of the American College of Cardiology regarding the use of digoxin and mortality in patients with AF.  Dr. Nancy Sokol hosts.

Dr. GanzDr. Ganz is a clinical cardiologist and Director of Cardiac Electrophysiology at the Heritage Valley Health System, in Western Pennsylvania, and Section Editor of the cardiac arrhythmias section in UpToDate.
  1. Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and Mortality in Patients With Atrial Fibrillation. J Am Coll Cardiol 2018; 71:1063.

Leonard Ganz, MD, FHRS, FACC Disclosure: Speaker’s Bureau: Amgen [Heart failure (Ivabradine)]; Pfizer, BMS [Anticoagulation (Apixaban)]; St. Jude Medical, Biotronik [Cardiac rhythm (Pacemaker/ICD)]; Lundbeck [Orthostatic hypotension (Northera)]. Consultant/Advisory Boards: Unequal Technologies [Commotio cordis (Protective equipment)]. Equity Ownership/Stock Options: Unequal Technologies [Commotio cordis (Protective equipment/apparel)].

PERC criteria for ruling out pulmonary embolism

Date Released: 5月 16 2018

Dr. Christopher Kabrhel discusses the PERC rule for evaluating patients with suspected pulmonary embolism and a trial exploring the effects of implementing the PERC rule in emergency departments in France, published in JAMA in February 2018. Dr. Nancy Sokol hosts.

Dr. KabrhelDr. Christopher Kabrhel is Associate Professor at Harvard Medical School, an Emergency Medicine physician at Massachusetts General Hospital, and author of several topics on pulmonary embolism for UpToDate.
  1. Freund Y, Cachanado M, Aubry A, et al. Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial. JAMA 2018; 319:559.

Dr. Christopher Kabrhel, MD, MPH Disclosure: Grant/Research Support: Siemens [Venous thromboembolism (D-dimer test)]; Janssen [Venous thromboembolism (Rivaroxaban)]; Diagnostica Stago [Venous thromboembolism (D-dimer test)]. Consultant/Advisory Board: Siemens [Venous thromboembolism (D-dimer test)]; Janssen [Venous thromboembolism (Rivaroxaban)].

Under-recognition of fetal alcohol spectrum disorders

Date Released: 5月 9 2018

This episode features Dr. Carol Weitzman discussing a recent study showing a higher incidence of fetal alcohol spectrum disorders in children than previously thought, as well as methods to raise awareness and improve detection. Dr. April Eichler hosts.

Dr. WeitzmanDr. Weitzman is Professor of Pediatrics and Director of the Developmental-Behavioral Pediatrics Program at the Yale School of Medicine. She is an author in the Pediatrics specialty at UpToDate.
  1. May PA, Chambers CD, Kalberg WO, et al. Prevalence of Fetal Alcohol Spectrum Disorders in 4 US Communities. JAMA 2018; 319:474.

Carol Weitzman, MD:
Other Financial Interests: HeartFlow (Investor).

ページ

ニュース&イベント